Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock

Executive Summary

Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.


Related Content

How To Conduct A Multi-Company Trial For Rare Pediatric Diseases
A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer
Real-World Evidence: Advice, Principles And Examples Emerge From FDA
Precision Medicine: Despite Gains, Optimum Use Far From Reached
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
Master Protocols In Practice
US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb
A Cautious Guide To The Interpretation Of Clinical Trials From NEJM
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts